莫西沙星治疗老年慢性阻塞性肺疾病急性发作临床分析被引量：1

导出

摘要目的评价莫西沙星在治疗老年慢性阻塞性肺疾病急性发作(AECOPD)的近期和远期疗效。方法将140例老年AECOPD患者随机分为两组,治疗组(68例)予莫西沙星0.4g(每日一次),静脉滴注;对照组(72例)予头孢曲松钠2.0g(每日一次),静脉滴注,两组疗程均为7～14d,观察临床总有效率、细菌清除率及再发间隔时间。结果治疗组临床总有效率为88.2%,细菌清除率为93.1%,再发间隔时间为110.4d;对照组临床总有效率为75.0%,细菌清除率为71.9%,再发间隔时间为91.4d。两组比较,差异均有统计学意义(均P<0.05)。结论莫西沙星治疗老年AECOPD临床疗效肯定,可减少AECOPD发作频率。

作者鞠俊强朱正太滕茂蓉李华翟月芳

机构地区泰州市人民医院老年科

出处《苏州大学学报（医学版）》 CAS 北大核心 2009年第4期719-720,共2页 Suzhou University Journal of Medical Science

关键词莫西沙星慢性阻塞性肺疾病老年

分类号 R978 [医药卫生—药品] R563 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献8

1马楠,崔德健.莫西沙星在慢性阻塞性肺病和慢性支气管炎急性加重时的应用[J].中国实用内科杂志,2002,22(12):765-766. 被引量：4
2慢性阻塞性肺疾病诊治指南[J].中华结核和呼吸杂志,2002,25(8):453-460. 被引量：5092
3Snow V, Lascher S, Mottur-Pilson C, et al. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease [J]. Ann Intern Med,2001,134(7): 595-599.
4中华人民共和国卫生部药政局.新药(西药)临床研究指导原则汇编[S].1993:2-6.
5Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,2000,161 (5): 1608-1613.
6李晓霞.治疗社区获得性呼吸道感染的新一代氟喹诺酮类药物——莫西沙星[J].中华内科杂志,2001,40(9):640-642. 被引量：65
7MacNee W. Acute exacerbations of COPD [J]. Swiss Med Wkly, 2003,133(17-18):247- 257.
8Miravitlles M. Exacerbation of chronic obstructive pulmonary disease : when are bacterial important [J]? Eur Respir,2002,36(Suppl) :9-19.

二级参考文献16

1[1]Barman BJA,Wiseman LR.Moxifloxacin.J Drugs,1999,57(3):363-373
2[2]Chodosh S,DeA bate CA,Haverstock D,et al.Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis.Respir Med,2000 Jan,94(1):17-26
3[3]Bauer T,Landen H.Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis.Clin Drug Invest,2002,22(10):641-651
4[4]DeAbate CA,Mathew CP,Warner JH,et al.The safety and efficacy of short course(5-day)moxifloxacin vs.azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.Respir Med,2000 Nov,94:1029-37
5[5]Wilson R,Kubin R,Ballin I,et al.Five day moxifloxacin therapy compared with 7-day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.J Antimicrob Chemother,1999,44:501-13
6[6]Baz MN,Jannetti W,Villanueva C,et al.The efficacy and tolerability of moxifloxacin compared with trovafloxacin in the treatment of acute sinusitis.Today Ther Trends,1999,17(4):303-19
7BallP.Fluoroquinolonesafetyandtolerability[].Proceedingoffirstinternationalmoxifloxacinsymposium.1999
8Souli M,Wennersten CB,Eliopoulous GM.In vitro activity of BAY 128039, a new fluoroquinolone, against species representative of respiratory tract pathogens[].International Journal of Antimicrobial Agents.1998
9Bradford WZ,Daley CL.Multiple drug-resistant tuberculosis[].Infectious Diseases in Clinical Practice.1998
10Aldridge KE,Ashcraft DS.Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes[].Antimicrobial Agents and Chemotherapy.1997